Augmented ePRO: A Practical Solution to an Industry-wide Problem
The subjectivity that characterizes ePRO can be challenging to overcome, compromising data accuracy and trial endpoints. We’ve responded to this industry-wide problem with a practical solution: Augmented ePRO. Our breakthrough offer combines the ease of ePRO with the accuracy of expert rating, all centralized in a single platform.
The Digital Trial Solution for Your Digital Therapeutic
For innovative digital therapeutic and diagnostic companies, traditional trial methods are antiquated – producing poor results in a slow and expensive way. You need a partner to develop a decentralized clinical trial that accelerates your timelines and works with your tech. Meet ObvioHealth.
Virtual Clinical Trials: Enhancing the Patient Experience with Digital Technologies
The best clinical virtual trials technologies support and enhance human connection and the patient experience. Learn how digitally enabled trials are empowering participants and study teams and delivering better data.
ObvioHealth, a leading global Virtual Research Organization (VRO) pioneering end-to-end decentralized clinical trial solutions, announces today its inclusion in Inc. Magazine’s annual list of the nation’s fastest-growing private companies.
Traditionally, electronic patient reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones.
ObvioHealth, a leading global Virtual Research Organization (VRO) pioneering end-to-end decentralized clinical trial solutions, announces the development of two novel digital instruments to increase accuracy and reduce patient/caregiver burden in pediatric clinical trials.
ObvioHealth, a leading global Virtual Research Organization (VRO) delivering end-to-end decentralized clinical trial solutions, announces it has completed the first fully virtual urogynecology study in partnership with trial sponsor, Renovia, Inc. (Renovia). The trial validated the efficacy of Renovia’s leva® Pelvic Health System on women’s incontinence, a health concern that affects 62% of U.S. adult women.
In our conversations with trial sponsors, ObvioHealth often tackles common misconceptions about decentralized clinical trials (DCTs). These myths hinder our industry’s evolution by keeping sponsors from designing optimal trials that deliver better data with higher retention and compliance rates.
ObvioHealth and 1nHealth announce today a joint initiative to smooth the transition to hybrid and decentralized clinical research. The initiative focuses on supporting clinical trials that may be struggling due to suboptimal protocol design, imprecise recruitment strategies, maladapted technology options or ailing site teams.According to clinicaltrials.gov, there are about 1,600 suspended trials at present.
This study collected and compared stool ratings from caregivers (Group A), central raters (Group B), and pediatric gastroenterologists (Group C) to discover whether the level of stool consistency of a given photo is more prone to inter-rater variability. The study's results evidence inter-rater variability that is different across Bristol Stool Scale (BSS), which motivates research into standardized training or automated scoring, with a special emphasis on BSS.
Novotech, a leading biotech specialist CRO in the Asia-Pacific region, and virtual research organization (VRO) partner ObvioHealth have been selected as finalists for the Clinical Partnership of the Year Citeline Award by Informa Pharma Intelligence. ObvioHealth is Novotech’s preferred provider for virtual clinical trials in APAC, while Novotech is ObvioHealth’s preferred CRO in the region for hybrid and virtual trials.
NEW YORK, September 30, 2021 - ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial in Australia, using a combination of in-home data collection methods that will reduce and in some cases eliminate the need for follow-up visits to clinics.
NEW YORK – September 14, 2021 - ObvioHealth, a global virtual research organization (VRO), announces key hires to round out its executive leadership team. Seeded four years ago by SGI, ObvioHealth has entered into a phase of more rapid growth and a need for an upsized team to address market demand.
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
Introducing Scott Clark as ObvioHealth's Chief Commercial Officer. Scott has had a distinguished and successful 25-year career in developing successful commercial strategies for global enterprises in the pharmaceutical, biotechnology, healthcare and technology industries.
In a recent study, we found that caregivers both underreported and overreported certain stool consistencies compared to clinician ratings. We need to make it easier for parents to report in clinical trials. See why digital image capture is an improved method for assessments of treatment efficacy and health status for pediatric GI research.
Unstructured data collection from image capture technology can be harnessed to improve the quality of patient-reported data and serve as the bedrock for the training of new algorithms that can help clinicians more accurately diagnose disease.
ObvioHealth, a global Virtual Research Organization(VRO), announces it has raised $31 million in its latest round of financing.The round was led by two new partners: Dedalus Group, an international healthcare IT and diagnostic software provider, leader in Europe and backed by Ardian, and Novotech Health Holdings Pte. Ltd.(“Novotech”), Asia Pacific’s highest revenue biotech-specialistCRO in 2020.
NEW YORK – June 7, 2021 – ObvioHealth, a global virtual research organization (VRO), is bringing clinical trial data fully into the continuum of care through a new strategic partnership with Dedalus Group, the leading healthcare and diagnostic software solutions provider in Europe.
ObvioHealth will integrate Hyfe's technology into its decentralized clinical trials platform and smartphone app to capture and analyze coughing events.
ObvioHealth, a global virtual research organization or VRO, today announced the launch of a hybrid clinical trial for the treatment of COVID-19, using an innovative study design with digital data capture to remotely monitor patient vitals.
ObvioHealth, a global Virtual Research Organization (VRO), announces its next generation platform offering enhanced remote patient monitoring capabilities for the company’s end-to-end decentralized clinical trial solutions.
ObvioHealth, a global virtual research organization (VRO), and GI Alliance, one of the nation's largest independent gastroenterology services organization, jointly announce anew partnership to create better clinical trial experiences through the use of decentralized clinical trial designs.
ObvioHealth, a leading virtual health research organization or VRO, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March.
A research study designed around the needs of its participants is more likely to deliver better data, a product of optimized compliance and engagement. By pairing a versatile digital solution with an accommodating protocol design, ObvioHealth can offer maximum convenience to those who matter most: the people who produce the data. The result? A collection of real-world data points and enhanced insights.
In the clinical trial space, patient concerns that must be addressed with tact. Whether delivering potentially life-altering news, or discussing a health-related concern, I find digital interaction to be the most prudent approach to sustaining engagement and reducing dropout. Here are five real-life examples of this strategy at-work.
The U.S. FDA is aware the drug approval process can often be strenuous, consuming large amounts of time and money. That’s why they’ve made a commitment to consider real-world evidence in the approval of new drug indications resulting in a more efficient approach for manufacturers.
ObvioHealth, a digital CRO, recently completed a clinical trial solely using a virtual site model (no physical site visits) which would have likely proved futile in the traditional study format, of which requires multiple site visits. This article will further analyze the rationale behind this claim.
Our team recently completed a clinical trial tasked with measuring the efficacy of a dietary supplement as an intervention for adults with an elevated blood pressure, or stage I hypertension. By employing a hybrid study model, sustaining patient engagement, and reducing resources required of the patient and study team, we successfully beat the dropout allowance.
All clinical trials require resource consumption from both the study team and participant. The following infographic will detail the differences in resources required in the digital (hybrid) model compared to that of the traditional “brick and mortar” model.
Digital patient-centric clinical trials (PCT) are often carried out in the hybrid setting (minimizing site visits and maximizing the use of a virtual site), or the site-less setting (solely using the virtual site). The pairing of a digitalized PCT with social media targeting increases the probability of successful enrollment.
There are more than 270,000 clinical research trials going on in the U.S. and other countries currently listed on ClinicalTrials.gov. These trials are helping to advance medial research for better treatments of diseases and conditions. However, before decided to participate in one, there are a number of items to consider first.
In the first part of our two-piece series exploring minority participation in clinical trial research, we examine the numerous challenges to securing diversity in clinical trials, and the consequences of primarily white patient populations.
Data collected from you as a participant is called individual participant data (IPD), that information is transformed into de-identified data when researchers do their analyses, meaning the ability to determine the identity of an individual participant is removed from the data.